CD131 antagonism blocks inflammation, emphysema and fibrosis in an asthma‐COPD overlap mouse model originating in early life

CD131 signalling coordinates multiple pathological pathways that drive airway inflammation and lung remodelling in ACO. Hence, CD131 antagonism represents a novel approach to combating the immunopathology in the complex ACO setting.